Novo Nordisk’s Q4 2026 earnings beat driven by Wegovy pill demand

Novo Nordisk’s oral Wegovy sales will outpace expectations, contributing significantly to Q4 2026 revenue growth. Oral formulations are expected to cannibalize a portion of injectable sales but drive overall market expansion.

earnings · Prediction Market

Implied probability (Yes)

65%

Closes

2027-01-31

More earnings markets

• Forum AI raises $50M+ in Series B funding by 2027-03-31 — 60% Yes
• Anthropic's compute deal with xAI will underperform revenue targets by Q4 2026 — 70% Yes
• Sadi Thermal Machines secures $50M+ funding round by 2027 — 70% Yes
• Lime achieves profitability within 12 months post-IPO — 55% Yes
• SK Hynix ADRs to price at or above midpoint range by July 10 — 75% Yes
• Flexjet stock rises 15% by Q4-2027 on fuel cost advantage — 70% Yes
• Alibaba's Q2 2026 cloud revenue growth falls below 20% — 78% Yes
• Driving instructor revenue drops 15% in Q3 2027 due to test booking changes — 68% Yes

Browse all earnings markets →